The objective of this study is to investigate the effects of berberine chloride and hyperthermia on the expression of Osterix (Osx), Runt-related transcription factor 2 (RUNX-2), receptor activator of nuclear factor kappa-B ligand (RANKL), cyclin-dependent kinase 2 (CDK2), CDK4, interleukin (IL)-6 and IL-11 genes.Read More.
A groundbreaking tumour-highlighting technology – OTL38 – enhances the visualisation of lung cancer tissue, providing surgeons with a significantly better chance of finding and removing more cancer than previously possible.Read More.
Zika virus infection can stunt neonatal brain development, a condition known as microcephaly, in which babies are born with abnormally […]Read More.
UK scientists have identified a new way to kill pancreatic cancer cells by ‘pulling the plug’ on the energy generator that fuels calcium pumps on their cell surface.Read More.
Findings related to FLASH Radiotherapy could pave a new path for the future for cancer therapyRead More.
The red, tube-shaped flowers of the firecracker bush (Bouvardia ternifolia), native to Mexico and the American Southwest, attract hummingbirds. The […]Read More.
In a new qualitative study, a team of scientists at Dartmouth and Dartmouth-Hitchcock’s Norris Cotton Cancer Center and the Breast Cancer Surveillance Consortium led by Karen Schifferdecker, PhD, MPH, and Anna Tosteson, ScD, sought to explore women’s knowledge and perceptions of breast density and experiences of breast cancer screening across three states with and without notification laws.Read More.
Immune checkpoint inhibitors are important medications that boost the immune system’s response against certain cancers; however, they tend to be ineffective against glioblastoma, the most deadly primary brain tumour in adults. New research in mice led by investigators at Massachusetts General Hospital (MGH) and the University of Florida reveals a promising strategy that makes glioblastoma susceptible to these medications.Read More.
A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.Read More.